CD8A and hepatocellular carcinoma: Even though studies putting forward the role of TIGIT/DNAM as a regulator of HCC are still particularly scarce in the literature, one recent study reports that the blockade of TIGIT enhanced the antitumor activity of CD8+ T cells during the progression of HBV-related HCC in a spontaneous HCC mouse model.